8-K: FitLife Brands Reports Strong Q3 2024 Results Driven by Online Sales and Strategic Acquisitions

FitLife Brands announced a 15% increase in total revenue and a 41% increase in adjusted EBITDA for the third quarter of 2024, driven by strong online sales and the performance of recent acquisitions.

Summary

• FitLife Brands reported a total revenue of $16.0 million for the third quarter of 2024, a 15% increase compared to the same period in 2023.
• Online sales accounted for 68% of total revenue, reaching $10.8 million, a 14% increase year-over-year.
• The company's gross margin improved to 43.8% from 41.0% in the third quarter of 2023.
• Net income for the quarter was $2.1 million, up from $1.7 million in the prior year.
• Basic earnings per share were $0.46, and diluted earnings per share were $0.43, compared to $0.38 and $0.35, respectively, in the third quarter of 2023.
• Adjusted EBITDA increased by 41% to $3.6 million.
• The company's net debt stood at $9.5 million, with $14.3 million outstanding on term loans and $4.7 million in cash.
• Recent acquisitions, including Mimis Rock Corp (MRC) and MusclePharm assets, contributed $1.3 million in wholesale revenue.
• Legacy FitLife wholesale revenue declined by $0.5 million, or 12%, compared to the same period last year.
• Adjusted EBITDA for the last twelve months was $13.4 million, including four full quarters of MRC's performance and approximately three and a half quarters of MusclePharm's performance.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, strategic acquisitions, and positive management commentary. The company is showing strong growth and profitability, with some minor challenges in the wholesale channel.

Positives

• The company experienced a significant increase in total revenue, driven by strong online sales.
• Gross margins improved, indicating better profitability on sales.
• Net income and earnings per share saw substantial growth compared to the previous year.
• Adjusted EBITDA increased significantly, reflecting improved operational efficiency.
• The company has reduced its net debt, indicating a stronger financial position.
• The MRC brands collective contribution of approximately $9.4 million over the last twelve months compares very favorably to the $17.1 million acquisition price.
• The company is seeing improvements in the rate of decline in retail sales of FitLife products.
• The company has secured new wholesale partners for MusclePharm and is launching a new product line.

Negatives

• Legacy FitLife wholesale revenue declined by 12%, indicating challenges in traditional retail channels.
• MusclePharm revenue decreased 8% sequentially from the second quarter of 2024 to the third quarter of 2024.
• MRC's skin care brands experienced a 33% revenue decline due to strategic market exits and price increases.
• The company's wholesale revenue continues to be challenged by declining customer counts in brick-and-mortar stores.

Risks

• The company faces challenges in the wholesale channel due to declining customer counts in brick-and-mortar stores.
• The performance of acquired brands may fluctuate, impacting overall results.
• The company's ability to continue to grow revenue and achieve positive cash flow is subject to various risks and uncertainties.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company is focused on growing revenue, particularly through online channels and new product launches, and continues to evaluate potential M&A opportunities. The company is launching the new MusclePharm Pro Series in a pilot program in the first quarter of 2025.

Management Comments

• Dayton Judd, the company's Chairman and CEO, expressed satisfaction with the company's strong performance.
• He noted the growth of the Dr. Tobias brand within MRC, despite reduced advertising spend.
• He highlighted the improved profitability of MRC's skin care brands after strategic market exits and price increases.
• He mentioned the positive impact of online sales growth offsetting wholesale declines for Legacy FitLife brands.
• He expressed optimism about recent wins for MusclePharm and the new MusclePharm Pro Series.
• He stated that the company's balance sheet is strong, with net debt representing approximately 0.7x adjusted LTM EBITDA.

Industry Context

The company's focus on online sales aligns with the broader trend of e-commerce growth in the health and wellness sector. The strategic acquisitions of MRC and MusclePharm are aimed at expanding the company's product portfolio and market reach. The company is facing similar challenges to other companies in the sector with declining brick and mortar sales.

Comparison to Industry Standards

• FitLife's 15% revenue growth is strong compared to the average growth rate in the nutritional supplement industry, which is estimated to be in the single digits.
• The 41% increase in adjusted EBITDA is significantly higher than the industry average, indicating strong operational performance.
• The company's gross margin of 43.8% is competitive with other companies in the sector, such as GNC and Vitamin Shoppe, which typically have gross margins in the 40-50% range.
• The company's focus on online sales is in line with the trend of direct-to-consumer sales in the industry, which is becoming increasingly important for growth.
• The company's debt to EBITDA ratio of 0.7x is relatively low, indicating a strong financial position compared to some competitors with higher leverage.

Stakeholder Impact

• Shareholders will likely view the results positively due to the strong financial performance and growth.
• Employees may be positively impacted by the company's success and growth prospects.
• Customers will benefit from the company's continued focus on innovative and proprietary products.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors will likely view the company's reduced debt and strong financial position favorably.

Next Steps

• The company will continue to focus on growing revenue through online channels and new product launches.
• The company will continue to evaluate potential M&A opportunities.
• The company will launch the new MusclePharm Pro Series in a pilot program in the first quarter of 2025.

Key Dates

Keywords

nutritional supplements, wellness products, online sales, EBITDA, acquisitions, gross margin, net income, wholesale revenue, Mimis Rock Corp, MusclePharm